As usage of the medications increases, Circana research indicates deli and produce could be bright spots for spending.

For overweight or obese individuals without diabetes, but with pre-existing cardiovascular disease, semaglutide (Ozempic, Wegovy) is not cost-effective at current pricing, new research shows.

The evolution of AI, more limited-time product offerings and GLP-1 use for weight loss are among the issues expected to play a more prominent role this year.